Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Exelixis to start new combo cancer trials with Bristol-Myers and Roche

Monday, February 27, 2017 9:03
% of readers think this story is Fact. Add your two cents.

Exelixis Inc (NASDAQ:EXEL) has agreed two new collaborative trials for solid tumours and other cancers with pharma giants Bristol-Myers Squibb and Roche.

With Bristol-Myers (NYSE:BMY), Exelisis will combine Cabometyx, a small molecule inhibitor of receptor tyrosine kinases, with blockbuster PD-1 immunotherapy drug Opdivo (nivolumab).

The co-funded clinical development program is scheduled to include a phase three pivotal trial in first-line renal cell carcinoma, with additional trials planned in bladder cancer, hepatocellular carcinoma (HCC) and others.

“The safety and efficacy data from the phase 1 clinical trial evaluating CABOMETYX in combination with Opdivo are consistent with the preclinical scientific rationale for combining these two therapeutic modalities,” said Michael Morrissey, Exelixis’s chief executive.

Roche, meanwhile, has agreed to collaborate on an early stage study for a combo treatment using drugs from the two companies to treat advanced kidney, bladder and other genitourinary tumours.

The phase 1b dose escalation study will evaluate the safety and tolerability of cabozantinib, Exelixis’ tyrosine kinase inhibitor (TKI), in combination with atezolizumab, Roche’s anti-PD-L1 immunotherapy.

Exelixis will be the sponsor of the trial and Roche will provide atezolizumab.

Sumanta Kumar Pal, co-director, Kidney Cancer Program at City of Hope, and principal investigator in the study, said. “The combined approach of tyrosine kinase inhibition with cabozantinib alongside immune-checkpoint inhibition has already shown promise in an early phase 1 clinical trial.

Exelixis shares rose 7% to US$23.19.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.